Management of Renal Injuries From Military Combat Trauma: The Department of Defense Trauma Registry Experience.

Objective: To evaluate the severity and management of renal injuries during the Global War on Terror (GWOT) using the Department of Defense Trauma Registry (DODTR).

Methods: Data was analyzed from the DODTR from 2007-2023. Patients with renal injuries were identified using ICD-9 codes.

Emulsion-LARP method: Optimization of demulsifier for synthesis of methylammonium lead bromide nano-structures.

An understanding on the influence of the type of demulsifier used on the degree of crystallization in emulsion process-grown organic-inorganic halide perovskite nanocrystals is presently lacking. We conducted a detailed investigation on the structural and optical properties of methylammonium lead bromide (CHNHPbBr) nano-structures synthesized using the emulsion-ligand-assisted re-precipitation method with three different demulsifiers (acetone, -butanol, and butanol). Structural analysis conducted using X-ray diffraction, HRTEM, and Raman studies showed that -butanol served as the best demulsifier among the three.

Self-assembled nickel(II)-centered metal-organic square grid complexes for CO sensing.

Detection and monitoring of hazardous CO gas are essential for ensuring human health and environmental safety, which form part of Goal 13 of the United Nations Sustainable Development Goals (SDGs). Metal-organic square complexes in thin-film forms are explored in this work for the first time as CO gas sensors. Two new Ni(II) metal-organic square grid complexes [Ni(HL)]Cl·26HO (1) and [Ni(HL)] (BF)·20HO (2) were achieved by self-assembly, utilizing 1,5-bis(2-benzoylpyridine) thiocarbohydrazone (HL) as building blocks.

Comparative efficacy of immunotherapy-based treatment versus chemotherapy-only in patients with unresectable NSCLC with disease progression post chemoradiation and durvalumab.

Introduction: The current standard of care for fit patients with unresectable stage III NSCLC involves concurrent chemoradiation (CRT) followed by durvalumab. Disease recurrence occurs in approximately 2/3 of patients, often necessitating subsequent systemic therapy. The only available data about re-challenge immune checkpoint blockers (ICB) in this setting derives from small retrospective series.

Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry.

Background: Pembrolizumab monotherapy is an established front-line treatment for advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) tumor proportion score (TPS)≥50%. However, real-world data on its long-term efficacy remains sparse.

Methods: This study assessed 5-year outcomes of first-line pembrolizumab monotherapy in a large, multicenter, real-world cohort of patients with advanced NSCLC and PD-L1 TPS≥50%, referred to as Pembro-real 5Y.